Radiolabeled methotrexate as a diagnostic agent of inflammatory target sites: A proof-of-concept study

Maria Papachristou, George A. Kastis, Petros Z. Stavrou, Stavros Xanthopoulos, Lars R. Furenlid, Ioannis E. Datseris, Penelope Bouziotis

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Methotrexate (MTX), as a pharmaceutical, is frequently used in tumor chemotherapy and is also a part of the established treatment of a number of autoimmune inflammatory disorders. Radiolabeled MTX has been studied as a tumor-diagnostic agent in a number of published studies. In the present study, the potential use of technetium-99m-labelled MTX (99mTc-MTX) as a radiotracer was investigated for the identification of inflammatory target sites. The labelling of MTX was carried out via a 99mTc-gluconate precursor. Evaluation studies included in vitro stability, plasma protein binding assessment, partition-coefficient estimation, in vivo scintigraphic imaging and ex vivo animal experiments in an animal inflammation model. MTX was successfully labelled with 99mTc, with a radiochemical purity of >95%. Stability was assessed in plasma, where it remained intact up to 85% at 4 h post-incubation, while protein binding of the radiotracer was observed to be ∼50% at 4 h. These preclinical ex vivo and in vivo studies indicated that 99mTc-MTX accumulates in inflamed tissue, as well as in the spinal cord, joints and bones; all areas with relatively high remodeling activity. The results are promising, and set the stage for further work on the development and application of 99mTc-MTX as a radiotracer for inflammation associated with rheumatoid arthritis.

Original languageEnglish (US)
Pages (from-to)2442-2448
Number of pages7
JournalMolecular Medicine Reports
Volume17
Issue number2
DOIs
StatePublished - Feb 2018

Keywords

  • Hydroxyapatite
  • Imaging
  • Inflammation
  • Methotrexate
  • Radiolabeling
  • Rheumatoid arthritis
  • Technetium-99m

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Radiolabeled methotrexate as a diagnostic agent of inflammatory target sites: A proof-of-concept study'. Together they form a unique fingerprint.

  • Cite this

    Papachristou, M., Kastis, G. A., Stavrou, P. Z., Xanthopoulos, S., Furenlid, L. R., Datseris, I. E., & Bouziotis, P. (2018). Radiolabeled methotrexate as a diagnostic agent of inflammatory target sites: A proof-of-concept study. Molecular Medicine Reports, 17(2), 2442-2448. https://doi.org/10.3892/mmr.2017.8166